Myriad Genetics reported $-4800000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Accelerate Diagnostics AXDX:US -17170000 1.89M
Agilent A:US $ 514M 48M
Becton, Dickinson and BDX:US $ 1182M 180M
Bio Rad Laboratories BIO:US $ 126.62M 48.91M
Biocept BIOC:US $ -2.3M 0.02M
Bruker BRKR:US $ 107.6M 17.5M
Danaher DHR:US $ 2757M 20M
Exact Sciences EXAS:US $ -101.13M 28.2M
Hologic HOLX:US $ 347.9M 352.2M
Illumina ILMN:US $ 124M 151M
Johnson & Johnson JNJ:US $ 8036M 1273M
Mettler Toledo International MTD:US 299.54M 42.2M
Myriad Genetics MYGN:US $ -4.8M 2.9M
Pacific Biosciences Of California PACB:US $ -67.79M 7.24M
Perkinelmer PKI:US $ 420.38M 11.6M
Quest Diagnostics DGX:US $ 495M 136M
Repligen RGEN:US $ 71.08M 1.53M
Thermo Fisher Scientific TMO:US $ 2861M 821M
Veracyte VCYT:US $ -0.94M 7.75M
Waters WAT:US $ 233.88M 5.74M